StockNow
Calendar
Log in
Global Markets

AstraZeneca's (AZN) Tezspire demonstrates statistically significant and clinically meaningful improvements in the co-primary endpoints of histologic remission and the frequency and severity of dysphagia

StockNow breaking-news AI analysis

The October 20 headline reports improvements in both Tezspire co-primary endpoints; earlier trial reports provide study context but no numerical endpoint results in the retrieved evidence.

1 stocks
AZNAstraZeneca PLC$168.50Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Politics

Google Cloud (GOOGL) says that "Multiple services are experiencing issues in the europe-west2 region"

GOOGLU.S. Economy

US ADP Employment Change Weekly 18.5K (Prev. 24.75K)

ADPPolitics

Mediation efforts said that "Qatar and Pakistan presented a 'compromise proposal' that meets the demands of both the American and Iranian sides", Al Araby Al Jadeed reports citing sources